Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Surveys and Questionnaires × Tumor-Agnostic × Clear all

Phase

Status

Completed 40 Recruiting 7 Unknown 3 Active not recruiting 3 Withdrawn 2 Terminated 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 10 Gastrointestinal 8 Gynecologic 7 Other hematologic neoplasm 6 Genitourinary 6 Head & Neck 5 Plasma cell 4 Lymphoid 4 Sarcoma 3 Myeloid 3 Thoracic 2 Endocrine 2 Dermatologic 2 Classical hematology 2 Tumor-Agnostic 1 Other neoplasm 1 Other 1 NET 1

Conditions

Interventions

Gemcitabine 12 pembrolizumab 9 Irinotecan 7 Erlotinib Hydrochloride 7 Carboplatin 7 Capecitabine 7 Nivolumab 6 Everolimus 6 Blood Specimen Collection 6 Paclitaxel 5 Docetaxel 5 Cisplatin 5 130-nm albumin-bound paclitaxel 5 trametinib 4 Lapatinib 4 Fluorouracil 4 Cyclophosphamide 4 Cetuximab 4 Albumin-Bound Paclitaxel 4 vadimezan 3 temsirolimus 3 atezolizumab 3 abemaciclib 3 Radiation 3 Pemetrexed 3 Magnetic Resonance Spectroscopy 3 Leucovorin 3 Ipilimumab 3 Imatinib Mesylate 3 tusamitamab ravtansine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03839940 2025-01-29

MIST

Alliance for Clinical Trials in Oncology

Phase 3 Terminated

39 enrolled 18 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡